Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
Recruiting · NCT03213002 · Registry updated 2026-06-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM | Brain Tumor, Primary, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), brain cancer, brain disorder, cancer, central nervous system cancer, central nervous system disorder, epithelial neoplasm, glioblastoma, glioma, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 / Phase 2 | 2026-06-01 | NCT03213002 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Northwell Health | 107 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Lenox Hill Brain Tumor Center | New York | United States | 6 |